Solengepras has showed early promise in addressing Parkinson’s disease’s (PD) overlooked non-motor burden, with Phase II data highlighting meaningful improvements in sleep and related symptoms despite limited motor gains. This reinforces a strategic shift beyond dopamine-centric care, signalling growing industry focus on holistic disease management, where targeting non-motor pathways could redefine treatment priorities and unlock differentiated value in early-stage Parkinson’s therapeutics, says GlobalData, a leading intelligence and productivity platform.

Reportedly, UK-based Cerevance has presented Phase II ASCEND (NCT06006247) trial data evaluating solengepras, a selective GPR6 inhibitor, in early PD, at the 2026 American Academy of Neurology (AAN) meeting.

The randomized, placebo-controlled study assessed solengepras 150 mg once daily over 12 weeks in untreated early PD patients. While the primary motor endpoint (MDS-UPDRS Parts II and III) showed only modest improvement versus placebo (−0.73), more meaningful effects were observed across non-motor domains.

Solengepras improved MDS-UPDRS Part I scores (−1.01 at Week 12), with consistent benefits in sleep-related measures, including MDS-UPDRS sleep components and Epworth Sleepiness Scale scores. Additional directional improvements were seen in autonomic symptoms and behavior, while cognition and mood remained largely unchanged.

Graysen Vigneus, Immunology Analyst at GlobalData, comments: “Solengepras’ mechanism, selective inhibition of GPR6 within the indirect basal ganglia pathway, represents a differentiated, non-dopaminergic approach. By modulating inhibitory signalling rather than directly targeting dopamine receptors, the therapy may address symptom pathways not adequately managed by existing treatments. This mechanistic profile aligns with the observed clinical data, where benefits were concentrated in non-motor domains rather than motor function.”

Non-motor symptoms such as sleep dysfunction, fatigue, and cognitive impairment are increasingly recognized as key drivers of disease burden in PD. However, the current therapies, including levodopa and dopamine agonists, offer limited efficacy in these areas. As highlighted by key opinion leaders interviewed by GlobalData, patients often prioritize non-motor symptom relief, particularly in early disease stages.

Solengepras demonstrated a favorable safety profile, with no serious adverse events or discontinuations reported. Adverse events were comparable to placebo, supporting its potential use in early-stage patients where tolerability is critical.

Vigneux concludes: “The emerging sleep benefits represent one of the most compelling aspects of the ASCEND data. Although derived from a relatively small cohort, the consistent improvements across sleep-related measures highlight a potentially meaningful therapeutic signal. The ongoing and future studies will be key in confirming the durability of these effects and optimizing endpoint selection to fully capture sleep-related outcomes.

 “Overall, solengepras represents a promising but early-stage approach to address a significant unmet need in PD. If future studies confirm sustained non-motor benefits, it could support a shift toward more holistic, symptom-driven treatment strategies beyond traditional motor-focused care.”